- Home
- NGNE vs MSB Comparison
NGNE vs MSB Comparison
Compare NGNE & MSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- MSB
- Stock Information
- Founded
- NGNE 2003
- MSB 1961
- Country
- NGNE United States
- MSB United States
- Employees
- NGNE N/A
- MSB N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- MSB Metal Mining
- Sector
- NGNE Health Care
- MSB Basic Materials
- Exchange
- NGNE Nasdaq
- MSB Nasdaq
- Market Cap
- NGNE 325.3M
- MSB 320.9M
- IPO Year
- NGNE N/A
- MSB N/A
- Fundamental
- Price
- NGNE $18.48
- MSB $30.92
- Analyst Decision
- NGNE Strong Buy
- MSB
- Analyst Count
- NGNE 7
- MSB 0
- Target Price
- NGNE $41.86
- MSB N/A
- AVG Volume (30 Days)
- NGNE 108.3K
- MSB 47.6K
- Earning Date
- NGNE 08-11-2025
- MSB 01-01-0001
- Dividend Yield
- NGNE N/A
- MSB 22.43%
- EPS Growth
- NGNE N/A
- MSB 335.65
- EPS
- NGNE N/A
- MSB 7.12
- Revenue
- NGNE N/A
- MSB $25,894,592.00
- Revenue This Year
- NGNE N/A
- MSB N/A
- Revenue Next Year
- NGNE N/A
- MSB N/A
- P/E Ratio
- NGNE N/A
- MSB $4.37
- Revenue Growth
- NGNE N/A
- MSB N/A
- 52 Week Low
- NGNE $6.88
- MSB $16.55
- 52 Week High
- NGNE $74.49
- MSB $37.00
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- MSB 54.91
- Support Level
- NGNE $19.59
- MSB $30.68
- Resistance Level
- NGNE $20.46
- MSB $33.25
- Average True Range (ATR)
- NGNE 1.23
- MSB 1.06
- MACD
- NGNE -0.20
- MSB -0.24
- Stochastic Oscillator
- NGNE 13.37
- MSB 27.41
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.